Happe Spine, a Grand Rapids, Mich.-based leader in the development of next generation orthopedic and spinal implants enabled by a material platform, closed on a $3.35m Series A funding.
The round was led by strategic investors from within the spine industry along with prominent and continuing investment by the Genesis Innovation Group’s cultivate(MD) Seed II Fund.
The company will apply the funding proceeds to launch an innovative interbody spinal fusion implant, with a focus on completing final regulatory testing and obtaining 510k approval, as well as scaling manufacturing operations and the production of implant and instrument inventory. Several new strategic leadership and staff positions within the company will also be added.
Happe Spine is a medical device development company that designs and commercializes innovative spinal implants utilizing the HAPPE orthopedic material platform of HydroxyApatite Porous PEek (HAPPE™). The patented material platform enables the advantages of monolithic implant porosity, which is currently only available in 3D-printed titanium, in PEEK for endplate-to-endplate osteointegration in interbody spinal fusion.
The material platform was originally invented at the University of Notre Dame under the direction of Dr. Ryan K. Roeder, PhD, Professor at the University and Founder of HAPPE Spine. The company has received three patents to date with additional patents pending. Dr. Roeder is a board member and Chief Technology Officer at HAPPE Spine.